
CPHI & PMEC China 2026
06/2026 – 06/2026
Bioland Pharma integrates R&D, production and sales of generic APIs, intermediates and excipients, focused mainly on high-potency niche products for anti-cancer and pediatric drugs. Its manufacturing sites have passed audits or inspections by the US FDA, EDQM and China's NMPA, with several products registered in China and abroad, and the company also offers one-stop CDMO services alongside high-quality intermediates and APIs.

コメントはありません。
評価とコメントを残す